
HAYA Therapeutics Secures $65M Series A to Advance RNA-Guided Therapies for Chronic Diseases
HAYA Therapeutics, SA, a biotechnology company pioneering precision RNA-guided regulatory genome targeting therapeutics that reprogram disease-driving cell states for rare, common, chronic and age-related diseases, announced that the company has raised $65 …